2.5 The Effect of DPP-4 Inhibitor, Alogliptin, on Bone Metabolism in Patients with Type 2 Diabetes Mellitus (1071-P)

Autor:	Yoji Hamada, Hidetada Ogata, Yuichiro Yamauchi, Yutaka Oiso, Eita Uenishi, Shin Tunekawa, Tetuji Okawa, Kouta Ishikawa, Ryoichi Banno, Yusuke Seino, Atsushi Iida, Atushi Ujiya, Hiroshi Arima
Rok vydání:	2013
Předmět:	medicine.medical_specialty business.industry Incretin Type 2 Diabetes Mellitus Increased Bone Density Type 2 diabetes medicine.disease Bone remodeling Endocrinology Internal medicine Diabetes mellitus medicine business Alogliptin Hormone
Zdroj:	Nederlands Tijdschrift voor Diabetologie. 11:85-85
ISSN:	1876-6242 1567-2743
Popis:	Type 2 diabetes (T2D) has been associated with a high risk of bone fractures. Recent studies showed that treatment with DPP-4 inhibitors could be associated with a reduced risk of bone fractures in the meta-analysis and incretin hormones increased bone density in experimental models.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::bf1c0e79a5432b7c8669e90771fee4a3 https://doi.org/10.1007/s12467-013-0039-1 Zobrazit plný text záznamu Full text from SpringerLink